ATTH | Atlas Therapeutics Corporation

Atlas Therapeutics Corp. ATTH

  ATTH traded two-and-a-half times its ten day average volume on Wednesday, as the stock continued to make higher lows; quite the positive sign. The stock managed to close at its high of day, logging a modest gain of 13% on the day.

Pertaining to the chart, the MACD appears to be kissing, and ready for the impending cross that we pointed out yesterday, so we think there is a fair chance to see ATTH finish the week strong.

One of the reasons why we like Atlas, is the employment of Dr. Carlon Colker, the inventor of the company’s flagship product, MYO-T12. Dr. Colker has quite a resume` beyond MYO-T12, including treatment and advisory of some of MMA’s top fighters, and a lead role in R&D for such health supplements as Metabolife, Ripped Fuel, and Xenadrine.
He has also authored several books, and still serves as an attending physician at world renowned medical center Beth Isreal in NY, as well as Greenwich Hospital in Connecticut.
According to Dr. Colker: “Of all the supplements I’ve developed, MYO-T12 is by far, the most effective anti-aging and fitness enhancement product you can buy.”
For those of you that may have missed the short ATTH pdf report we linked yesterday, why not take a look today, it is a good way to begin learning more about this ecxiting company.